Filip K Knop (MD, PhD) is a Professor of Endocrinology and Director of the Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, and Consultant Endocrinologist at Steno Diabetes Center Copenhagen.

Professor Knop has been involved in diabetes and metabolic research since his fellowship at The Distinguished Gifford Laboratories for Diabetes Research, University of Texas, Southwestern Medical Center in Dallas in 1999 (supervised by Professor Christopher B Newgard). His research centres on human metabolism, the pathophysiology of obesity and related disorders including type 2 diabetes and non-alcoholic fatty liver disease, regulation of appetite and food intake, and the therapeutic potential of factors involved in these processes. The Knop laboratory has reported several novel findings describing the integrative role of the gut and the liver in human pathophysiology.

Professor Knop has authored more than 460 peer-reviewed scientific publications and he has received several honours for his research, such as being named “Rising star” by the EASD in 2010, the DPLU/LUDC Nordic Prize for an Outstanding Young Diabetes Investigator (2011), Johan Quentin and Wife’s Prize for Outstanding Research (2014), The Capital Region of Denmark’s Global Excellence Prize (2014), The Thomsen Prize (2015), The Niels Schwartz Sørensen Prize (2017), The Danish Odd Fellowship’s Research Prize (2017), the European Journal of Endocrinology Prize 2018, and the Minkowski Prize 2019. Professor Knop has extensive teaching experience within the fields of human physiology and anatomy, internal medicine, clinical endocrinology and diabetology; and he has successfully supervised 50 PhDs.

Duality of Interest: Professor Knop has received research support / grants from Novo Nordisk and Zealand Pharma and speakers honorarium / fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Zealand Pharma. He has also received payments for membership of boards / advisory panels from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Zealand Pharma and fees for other educational activities from Astra Zeneca, Eli Lilly, Novo Nordisk and Zealand Pharma; together with payments for consultancy from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Zealand Pharma.
Date: Summer 2023